Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 15, 2025Deleted JournalOpen Access

Clinician’s knowledge and awareness of patient-reported outcomes in immune thrombocytopenia: Results of a national survey (ITP NET, GIMEMA Working Group Anemia and Thrombocytopenia)

View Full Paper
Ask AI
Bookmark
Share

Authors

EOEsther Natalie OlívaFEFabio EfficaceMVMaria Rosa Valvano

Discussion

Loading...

Member takes

Overview

National survey reveals limited clinician knowledge of patient-reported outcomes in immune thrombocytopenia, indicating training needs.

Key Points

  • Awareness of patient-reported outcomes among hematologists is limited, impacting care for immune thrombocytopenia patients.
  • Over half of the respondents used patient-reported outcomes clinically, and most had treated a median of 50 patients in the prior year.
  • Survey involved 63 hematologists across 49 centers, assessing their demographics and understanding of quality of life tools.
  • Significant knowledge gaps exist, particularly among hematologists with less clinical experience and exposure to immune thrombocytopenia.

Cite This Study

Olíva et al. (2025) studied this question.

synapsesocial.com/papers/68c235ccb210217d64771e55https://doi.org/10.1177/22799036251361377
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Patient survey in immune thrombocytopenia (<scp>ITP</scp>): Identifying unmet needs related to treatment and disease control in patients living in the United States2025
  2. 2A Qualitative Study on Patient Experience with Signs, Symptoms, and Daily Impacts of Immune Thrombocytopenia2025
  3. 3Exploring the Burden on Patients Living With and Receiving Treatment for Immune Thrombocytopenia ( <scp>ITP</scp> ): Patient and Physician Perceptions From the <scp>ITP</scp> World Impact Survey (I‐ <scp>WISh</scp> ) 2.02026
  4. 4Measuring success by different rulers: Heterogeneity in definition of outcomes in immune thrombocytopenia trials2025
  5. 5Real world experiences in the treatment of immune thrombocytopenia over a two-year period2026